Abstract
The purpose of this study was to develop a sensitive and rapid method for the determination of venlafaxine in human saliva. Blank saliva samples were obtained from healthy volunteers. Their extraction was carried out on SPE columns. Cartridges of the columns were washed with water and the adsorbate was eluted with methanol. The eluate was evaporated and the residue was dissolved in a mixture of acetonitrile and water (50:50, v/v). Venlafaxine was analyzed on a HPLC system with UV detection at 226 nm. The mobile phase was a mixture of acetonitrile and a phosphate buffer (30:70 v/v) at a flow rate of 1 mL min–1. Linearity of the calibration curve was obtained in the range of 1–1000 ng mL–1 of venlafaxine in saliva. The limit of detection was 1 ng mL–1 (S/N = 3) and the limit of quantification was 3 ng mL–1 (S/N = 10). The RSD values for intra–day study varied between 0.21 and 1.67% and those for inter–day study did not exceed 8.14%. The developed method was applied to the analysis of saliva samples without interference peaks and enabled determination of the venlafaxine concentration in depressed persons. The method can be useful for controlling intake of the drug by patients.
Keywords: Venlafaxine, human saliva, HPLC, SPE
Current Pharmaceutical Analysis
Title:Determination of Venlafaxine in Human Saliva by HPLC using Solid– Phase Extraction
Volume: 9 Issue: 2
Author(s): Ewelina Dziurkowska and Marek Wesolowski
Affiliation:
Keywords: Venlafaxine, human saliva, HPLC, SPE
Abstract: The purpose of this study was to develop a sensitive and rapid method for the determination of venlafaxine in human saliva. Blank saliva samples were obtained from healthy volunteers. Their extraction was carried out on SPE columns. Cartridges of the columns were washed with water and the adsorbate was eluted with methanol. The eluate was evaporated and the residue was dissolved in a mixture of acetonitrile and water (50:50, v/v). Venlafaxine was analyzed on a HPLC system with UV detection at 226 nm. The mobile phase was a mixture of acetonitrile and a phosphate buffer (30:70 v/v) at a flow rate of 1 mL min–1. Linearity of the calibration curve was obtained in the range of 1–1000 ng mL–1 of venlafaxine in saliva. The limit of detection was 1 ng mL–1 (S/N = 3) and the limit of quantification was 3 ng mL–1 (S/N = 10). The RSD values for intra–day study varied between 0.21 and 1.67% and those for inter–day study did not exceed 8.14%. The developed method was applied to the analysis of saliva samples without interference peaks and enabled determination of the venlafaxine concentration in depressed persons. The method can be useful for controlling intake of the drug by patients.
Export Options
About this article
Cite this article as:
Dziurkowska Ewelina and Wesolowski Marek, Determination of Venlafaxine in Human Saliva by HPLC using Solid– Phase Extraction, Current Pharmaceutical Analysis 2013; 9 (2) . https://dx.doi.org/10.2174/1573412911309020006
DOI https://dx.doi.org/10.2174/1573412911309020006 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quantitative Imaging Biomarkers and their Emerging Role
Current Medical Imaging Electroacupuncture Reduces Hemiplegia Following Acute Middle Cerebral Artery Infarction with Alteration of Serum NSE, S-100B and Endothelin
Current Neurovascular Research Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine Endogeneous Remyelination: Findings in Human Studies
CNS & Neurological Disorders - Drug Targets Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest
Current Alzheimer Research Should we Try to Alleviate Immunosenescence and Inflammaging - Why, How and to What Extent?
Current Pharmaceutical Design Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Physical Exercise and Yoga: As an Alternative Approach Towards COVID-19 Management
Current Traditional Medicine Preface
Current Psychopharmacology Problematic Use of the Mobile Phone: A Literature Review and a Pathways Model
Current Psychiatry Reviews Lipid Nanoparticles for the Delivery of Biopharmaceuticals
Current Pharmaceutical Biotechnology Elderly Patients with Migraine: An Open-Label Study on Prophylaxis Therapy with Levetiracetam
Central Nervous System Agents in Medicinal Chemistry Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
CNS & Neurological Disorders - Drug Targets How to Prevent Postpartum Relapse to Smoking
Current Pediatric Reviews Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Glutamate Binding-Site Ligands of NMDA Receptors
Current Medicinal Chemistry Modulation Effects of Piracetam and Ginkgo biloba on the Cognitive and Working Memory Functions: Psychometric Study
Current Psychopharmacology